NovoRapid FlexTouch
Rapid-acting insulin analogue (insulin aspart) delivered via a pre-filled pen for mealtime blood glucose control in diabetes mellitus
NovoRapid FlexTouch contains insulin aspart, a rapid-acting human insulin analogue used to lower blood glucose levels in people with type 1 and type 2 diabetes mellitus. Delivered through a discreet, pre-filled disposable pen with a light push-button, it begins working within 10 to 20 minutes of injection, making it well suited for use immediately before (or shortly after) meals. NovoRapid FlexTouch is a prescription medicine that should be used as part of an individualized diabetes treatment plan under the supervision of a healthcare professional.
Quick Facts
Key Takeaways
- NovoRapid FlexTouch (insulin aspart) is a rapid-acting mealtime insulin with an onset of 10-20 minutes, peak effect at 1-3 hours and a duration of action of approximately 3-5 hours.
- Inject immediately before a meal – or, if needed, within 5-10 minutes after starting to eat – because the insulin begins working faster than regular (soluble) human insulin.
- The most important side effect is hypoglycemia (low blood sugar). Always carry a fast-acting source of glucose and learn to recognize early warning signs such as sweating, trembling and hunger.
- Rotate injection sites within the abdomen, thigh or upper arm to prevent lipodystrophy, which can impair insulin absorption and worsen glycemic control.
- Store unopened pens in a refrigerator at 2-8 °C. Once in use, the pen can be kept below 30 °C for up to 28 days. Never freeze insulin and never share a pen between individuals.
What Is NovoRapid FlexTouch and What Is It Used For?
NovoRapid FlexTouch contains the active substance insulin aspart, a modified form of human insulin produced by recombinant DNA technology using genetically engineered Saccharomyces cerevisiae (baker's yeast). A single amino acid substitution — proline replaced by aspartic acid at position B28 of the insulin molecule — reduces the tendency of insulin molecules to cluster into hexamers after injection. The result is a faster transition to absorbable monomers, giving insulin aspart a more rapid onset and a shorter duration of action than regular soluble human insulin.
Insulin is a hormone produced by the beta cells of the pancreas that plays a central role in glucose metabolism. It enables muscle, fat and liver cells to absorb glucose from the bloodstream and simultaneously suppresses the liver's production of new glucose. In diabetes mellitus, the body either fails to produce insulin (type 1 diabetes) or cannot use insulin effectively (type 2 diabetes). Without adequate insulin action, blood glucose rises (hyperglycemia), which over time damages blood vessels, nerves, kidneys and the retina.
Because NovoRapid FlexTouch starts working within 10 to 20 minutes, it is specifically designed as a mealtime (bolus) insulin. This distinguishes it from intermediate-acting (NPH) and long-acting basal insulins such as insulin glargine, insulin detemir or insulin degludec, which are intended to provide a low, steady background insulin supply. In modern intensive insulin therapy — often referred to as basal-bolus therapy — both categories of insulin are used together to mimic the natural insulin secretion pattern of a healthy pancreas. NovoRapid is also widely used in continuous subcutaneous insulin infusion (CSII) pumps, where it is delivered in small, continuous doses that can be boosted around meals.
The FlexTouch delivery system is a disposable, pre-filled pen designed to be intuitive and low-force. Each pen contains 3 mL (300 units) of insulin aspart 100 units/mL. The dose selector can be set from 1 to 80 units per injection in 1-unit increments, and the end-of-dose click audibly confirms that the full dose has been delivered. The low activation force required to press the dose button makes FlexTouch particularly suitable for patients with reduced manual dexterity, including many older adults and people with arthritis.
NovoRapid FlexTouch is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and older. Specific clinical situations where it is used include:
- Type 1 diabetes mellitus, where insulin therapy is essential for survival from the time of diagnosis.
- Type 2 diabetes mellitus, when oral antidiabetic agents (such as metformin or sulfonylureas) or basal insulin alone no longer achieve adequate glycemic control.
- Gestational diabetes, when dietary modification does not control blood glucose during pregnancy (decision made by the treating obstetrician/endocrinologist).
- Diabetic ketoacidosis (DKA) and severe hyperglycemia, where it may be administered intravenously in a hospital setting under close supervision.
- Insulin pump (CSII) therapy in both adults and children with type 1 diabetes.
Internationally, NovoRapid is marketed in the United States under the brand name NovoLog, but the formulation, concentration and pharmacokinetic profile are identical. Insulin aspart is listed on the World Health Organization's Model List of Essential Medicines, reflecting its central role in diabetes management worldwide.
What Should You Know Before Taking NovoRapid FlexTouch?
Contraindications
NovoRapid FlexTouch must not be used in the following situations:
- Hypoglycemia: Never inject insulin when your blood glucose is already low. Administering insulin during hypoglycemia can cause dangerously low blood sugar, which may lead to unconsciousness, seizures, permanent brain injury or death.
- Known hypersensitivity: Do not use NovoRapid FlexTouch if you have experienced an allergic reaction to insulin aspart or any of the excipients in the formulation. Symptoms of severe allergy include generalized urticaria, difficulty breathing, wheezing, rapid heartbeat, sweating and a drop in blood pressure (anaphylaxis).
Warnings and Precautions
Before starting NovoRapid FlexTouch, discuss the following with your healthcare provider:
- Blood glucose monitoring: Regular self-monitoring of blood glucose (SMBG) is essential to verify that your dose, timing and diet are appropriate. Continuous glucose monitoring (CGM) systems can provide additional safety and pattern recognition. Your healthcare team will advise on target ranges and testing frequency.
- Hypoglycemia awareness: Learn to recognize the early warning signs of low blood sugar — sweating, trembling, rapid heartbeat, hunger, dizziness, difficulty concentrating — and carry fast-acting glucose (glucose tablets, juice or honey) at all times. Patients with long-standing diabetes, tight glycemic control, autonomic neuropathy or who take beta-blockers may have reduced hypoglycemia awareness.
- Changes in insulin regimen: Any change in strength, manufacturer, type (e.g. human insulin to analogue), species or method of manufacture can result in a change of dose. Such changes should only be made under medical supervision, and glucose monitoring should be intensified for at least the first 1-2 weeks.
- Impaired kidney or liver function: The liver and kidneys metabolize and clear insulin. Reduced function in either organ prolongs insulin action and can increase the risk of hypoglycemia. Dose adjustments and closer monitoring may be needed.
- Illness and infection: Fever, infection, surgery and trauma usually increase insulin needs (due to stress hormones such as cortisol and adrenaline). Gastrointestinal illness, nausea and vomiting may reduce food intake and lower insulin requirements. A sick-day management plan from your healthcare provider is strongly recommended.
- Physical activity: Exercise increases insulin sensitivity and can lower blood glucose both during and for several hours after activity. Dose and carbohydrate intake around exercise may need to be adjusted.
- Travel across time zones: Crossing more than two time zones may require adjustments to the timing and sometimes the dose of mealtime insulin. Discuss travel plans with your diabetes team before departure.
- Injection site rotation: Always rotate injection sites within the same general area (abdomen, thigh or upper arm) to reduce the risk of lipohypertrophy or lipoatrophy, which can impair insulin absorption and cause unexpected glucose swings.
- Thiazolidinediones (TZDs): Combining insulin with thiazolidinediones such as pioglitazone has been associated with fluid retention and, rarely, heart failure, especially in patients with pre-existing cardiovascular disease.
- Driving and operating machinery: Hypoglycemia may impair concentration and reaction time. Always check your blood glucose before driving a vehicle or operating machinery, and carry a fast-acting carbohydrate. Patients who experience impaired hypoglycemia awareness should discuss driving safety with their doctor.
Pregnancy and Breastfeeding
Insulin aspart can be used during pregnancy. Accumulated clinical data from randomized controlled trials and meta-analyses have not shown any adverse effect of insulin aspart on pregnancy outcomes or on the health of the fetus/newborn when compared with regular human insulin. Several studies suggest that post-meal glucose excursions are smaller with rapid-acting analogues such as insulin aspart than with soluble human insulin, which may be advantageous for maternal and fetal outcomes.
Insulin requirements typically decrease during the first trimester (often leading to increased hypoglycemia risk) and progressively increase during the second and third trimesters as placental hormones cause insulin resistance. Requirements drop rapidly after delivery and usually return to pre-pregnancy levels. Close monitoring and frequent dose adjustments are essential throughout pregnancy and the postpartum period, ideally within a specialist multidisciplinary team.
Insulin aspart can be used during breastfeeding. Insulin is a protein that is broken down in the infant's gastrointestinal tract and is not absorbed in biologically active amounts. However, breastfeeding women may need to adjust their insulin dose and carbohydrate intake, particularly during the first weeks postpartum and when night feeds reduce sleep.
Always tell your healthcare provider about every medicine you take, including over-the-counter medicines, herbal products and supplements. Many substances (steroids, thyroid hormones, antidepressants, antipsychotics, alcohol and even some herbal remedies) can affect blood glucose and may require adjustments to your insulin dose.
How Does NovoRapid FlexTouch Interact with Other Drugs?
Drug interactions with insulin are clinically important because they can shift glycemic control in either direction, sometimes dramatically. Some agents enhance the glucose-lowering effect of insulin, increasing the risk of hypoglycemia; others counteract insulin's action, leading to hyperglycemia. Still others (such as beta-blockers) do not change glucose directly but mask the warning symptoms of hypoglycemia, making it more dangerous.
The tables below summarize the most clinically relevant drug interactions with NovoRapid FlexTouch. The lists are not exhaustive. Patients should always inform every healthcare provider they see (including dentists, pharmacists and emergency staff) that they use insulin, and check with a pharmacist before starting any new medication or supplement.
Major Interactions (Increased Hypoglycemia Risk)
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Sulfonylureas (glimepiride, gliclazide, glipizide, glyburide) | Stimulate endogenous insulin secretion from pancreatic beta cells | High – Additive hypoglycemia risk; dose reduction of one or both agents may be required |
| GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) | Enhance glucose-dependent insulin secretion; slow gastric emptying | Moderate to High – Mealtime insulin dose often needs reduction when starting a GLP-1 agonist |
| SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) | Promote urinary glucose excretion; increase insulin sensitivity | Moderate – Hypoglycemia risk; also rare risk of euglycemic diabetic ketoacidosis |
| ACE inhibitors (ramipril, lisinopril, enalapril) | Improve insulin sensitivity; increase bradykinin-mediated glucose uptake | Moderate – Monitor glucose when starting or uptitrating |
| Non-selective beta-blockers (propranolol, carvedilol) | Blunt adrenergic hypoglycemia symptoms and delay recovery from hypoglycemia | High – Sweating may be the only remaining warning sign; use cardioselective agents where possible |
| Fibrates (fenofibrate, gemfibrozil) | Improve insulin sensitivity (PPAR-alpha activation) | Moderate – Monitor glucose when starting or stopping |
| Salicylates (high-dose aspirin, sulfonamides) | Displace insulin from protein binding; reduce gluconeogenesis | Moderate – Relevant mainly at anti-inflammatory doses |
| MAO inhibitors (phenelzine, tranylcypromine) | Potentiate insulin action via unclear mechanism | Moderate – Increased blood glucose monitoring recommended |
| Alcohol | Inhibits hepatic gluconeogenesis; can cause hypoglycemia unawareness | High – Risk of severe, delayed nocturnal hypoglycemia, especially when consumed without food |
Medications That May Reduce Insulin Effectiveness
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Corticosteroids (prednisone, dexamethasone, hydrocortisone) | Increase hepatic glucose output and peripheral insulin resistance | High – Insulin doses may need to increase by 50-100% during systemic steroid therapy; anticipate dose reduction on taper |
| Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide) | Reduce insulin secretion via hypokalemia; increase insulin resistance | Moderate – Monitor glucose and potassium; dose-dependent effect |
| Atypical antipsychotics (olanzapine, clozapine, quetiapine) | Increase weight and insulin resistance; directly affect beta-cell function | High – Can cause significant glycemic deterioration; rare cases of new-onset diabetes |
| Thyroid hormones (levothyroxine, liothyronine) | Increase hepatic glucose production and intestinal glucose absorption | Moderate – Insulin needs may change when thyroid function changes; monitor during titration |
| Oral contraceptives / estrogens | Reduce insulin sensitivity | Low to Moderate – Modest dose adjustments may be required |
| Sympathomimetics (salbutamol, terbutaline, epinephrine) | Stimulate glycogenolysis and gluconeogenesis | Moderate – Transient effect, especially during acute bronchodilator use |
| Protease inhibitors (HIV antiretrovirals) | Induce insulin resistance | Moderate – May precipitate or worsen diabetes |
| Octreotide / lanreotide | Suppress both insulin and glucagon secretion; unpredictable glucose effect | Moderate – Can cause either hypoglycemia or hyperglycemia depending on context |
Alcohol inhibits the liver's ability to produce new glucose (gluconeogenesis) and can cause severe, delayed hypoglycemia — sometimes occurring several hours after drinking or overnight. If you choose to drink alcohol, do so with food, in moderation, and consider testing your blood glucose before bed. Never drink alcohol on an empty stomach while using insulin, and make sure someone nearby knows how to treat hypoglycemia.
What Is the Correct Dosage of NovoRapid FlexTouch?
Insulin dosing is highly personalized and depends on many factors: type of diabetes, body weight, dietary pattern, physical activity, concurrent medications, pregnancy status and overall glycemic targets. There is no single "standard" dose of NovoRapid FlexTouch. The following guidance reflects general principles from the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), International Society for Pediatric and Adolescent Diabetes (ISPAD) and product labeling. Always follow your healthcare provider's specific instructions.
Adults
Type 1 Diabetes
Total daily insulin requirements in adults with type 1 diabetes typically range from 0.4 to 1.0 units/kg/day. Approximately 50% of the total daily dose is given as mealtime (bolus) insulin such as NovoRapid FlexTouch, divided over meals, while the remaining 50% is provided as basal insulin. Many patients calculate their mealtime dose using an insulin-to-carbohydrate (I:C) ratio (e.g. 1 unit of insulin per 10 grams of carbohydrate) and add a correction dose based on pre-meal blood glucose.
Type 2 Diabetes
In type 2 diabetes, NovoRapid FlexTouch is typically added when basal insulin alone is insufficient to control post-meal glucose excursions. A common starting strategy is 4 units or 10% of the basal dose injected before the main meal, with subsequent titration every 3-7 days (in 1-2 unit steps) based on post-meal glucose. Mealtime insulin may be added to one, two or all three main meals — often called basal-plus or full basal-bolus therapy, respectively.
Insulin Pump Therapy (CSII)
NovoRapid is commonly used in continuous subcutaneous insulin infusion pumps. Total daily insulin is usually set to 50% basal and 50% bolus, and patients receive small, individualized boluses around meals and for corrections. In automated insulin delivery (AID) systems, an algorithm adjusts basal delivery automatically based on continuous glucose monitoring data, with the patient still responsible for meal boluses.
Children and Adolescents (1 year and older)
Pediatric Dosing
Children with type 1 diabetes typically require 0.5 to 1.0 units/kg/day, rising to 1.0 to 2.0 units/kg/day during puberty because of pubertal insulin resistance. Mealtime insulin usually accounts for 40-60% of the total daily dose. Pediatric dosing must be supervised by a specialist team. Caregivers must be thoroughly trained in injection technique, carbohydrate counting, blood glucose monitoring, pattern recognition and hypoglycemia management before discharge. School staff should also have a written care plan.
Elderly Patients
Geriatric Considerations
In elderly patients, insulin therapy should begin with lower starting doses and cautious titration. Older adults are at increased risk of hypoglycemia because of reduced renal function, impaired counter-regulatory hormone responses, polypharmacy, irregular meals and cognitive impairment. Glycemic targets may be relaxed (for example, HbA1c 7.5-8.0% and fasting glucose below 8.3 mmol/L [150 mg/dL]) in frail older adults or those with limited life expectancy, as recommended by the ADA/EASD consensus on older adults. Simplified regimens (e.g. basal insulin plus oral agents, or one to two mealtime injections for the largest meal only) may be preferable when polypharmacy or cognitive issues make full basal-bolus regimens unsafe.
Renal or Hepatic Impairment
In patients with reduced kidney or liver function, insulin requirements may be reduced because both organs clear insulin and contribute to gluconeogenesis. Close monitoring and individualized dose reduction are recommended. There is no fixed dose-reduction formula; adjustments should be made empirically based on blood glucose readings.
Missed Dose
If you miss a dose of NovoRapid FlexTouch and it is still close to the meal (ideally within 10-15 minutes of starting to eat), you can inject the dose and continue eating. If significantly more time has passed, check your blood glucose: smaller correction doses may be more appropriate than the full mealtime dose to avoid late post-meal hypoglycemia. Never inject a double dose to make up for a missed one. Monitor your blood glucose more closely for the next 4-6 hours and consult your healthcare team if you are unsure.
Overdose
An overdose of insulin causes hypoglycemia, which can range from mild (treatable with oral glucose) to severe (requiring medical assistance). Symptoms include sweating, trembling, rapid heartbeat, confusion, blurred vision, slurred speech, aggression and loss of consciousness. Mild hypoglycemia can be treated by consuming 15-20 grams of fast-acting carbohydrate (4-5 glucose tablets, 150 mL fruit juice or regular soda). Recheck blood glucose after 15 minutes and repeat if still low. Follow with a longer-acting carbohydrate snack. Severe hypoglycemia, in which the patient cannot self-treat, is a medical emergency. Family members should be trained to administer intramuscular or nasal glucagon. If the person is unconscious or unable to swallow, call emergency services immediately.
NovoRapid FlexTouch is administered by subcutaneous injection into the abdomen (preferred site because of fastest absorption), thigh, upper arm or gluteal area. The insulin solution must appear clear and colourless — do not use if it is cloudy, discoloured or contains visible particles. Always use a new pen needle for each injection. After injecting, keep the needle under the skin for at least 6 seconds while watching the dose counter return to 0 to ensure the full dose is delivered. Never share a FlexTouch pen between individuals, even if the needle is changed, because of the risk of transmitting bloodborne infections.
What Are the Side Effects of NovoRapid FlexTouch?
Like all medicines, NovoRapid FlexTouch can cause side effects, although not everybody gets them. The frequency classifications below follow the Council for International Organizations of Medical Sciences (CIOMS) categories used in European and US regulatory labelling. They are based on controlled clinical trials and post-marketing surveillance of insulin aspart.
The most important side effect to understand is hypoglycemia. Every patient using insulin should be educated about recognition, self-treatment and prevention of low blood sugar. A healthcare team will work with the individual to minimize risk through careful dose adjustment, timing, dietary planning and use of monitoring technology.
Very Common (affects more than 1 in 10 people)
- Hypoglycemia – Low blood sugar causing sweating, trembling, rapid heartbeat, hunger, dizziness, confusion, blurred vision, headache, and in severe cases loss of consciousness or seizures. Severe hypoglycemia may require help from another person and glucagon or intravenous glucose.
Common (affects 1 to 10 in 100 people)
- Injection site reactions – Redness, swelling, bruising, pain, itching or a small lump at the injection site; usually mild and transient.
- Lipodystrophy – Lipohypertrophy (firm, rubbery fatty lumps) or lipoatrophy (thinning of fat) at injection sites; can affect insulin absorption.
- Peripheral edema – Mild swelling of the hands, feet or ankles, particularly at the start of insulin therapy or after intensification.
- Weight gain – Insulin promotes glucose storage and can lead to modest weight gain, especially in the first 6-12 months of therapy.
Uncommon (affects 1 to 10 in 1,000 people)
- Local allergic reactions – Urticaria, rash or persistent itching around the injection area. Most reactions resolve within days to weeks.
- Visual disturbances – Temporary blurred vision can occur when blood glucose control is rapidly improved, due to changes in lens refraction; typically resolves within weeks.
- Worsening of diabetic retinopathy – Rapid intensification of glycemic control can transiently worsen retinopathy. Ophthalmological assessment before intensification is recommended in high-risk patients.
- Peripheral neuropathy (insulin neuritis) – Rarely, rapid glucose improvement can cause painful neuropathy that usually resolves over months.
Rare (affects fewer than 1 in 1,000 people)
- Severe systemic allergic reactions (anaphylaxis) – Generalized rash, angioedema, bronchospasm, hypotension and shock; requires immediate emergency treatment.
- Hypokalemia – Insulin shifts potassium into cells, which can lower serum potassium. Risk is greatest with high-dose intravenous insulin (e.g. during diabetic ketoacidosis treatment).
- Insulin antibody formation – Usually clinically insignificant; very rarely, antibody-mediated changes in insulin requirements occur.
- Cutaneous amyloidosis at injection sites – Extremely rare; associated with chronic injection into the same site.
Seek immediate medical attention if you experience severe hypoglycemia with loss of consciousness or seizures; signs of a severe allergic reaction such as widespread rash, difficulty breathing, swelling of the face, tongue or throat; chest pain, confusion or a sudden, severe worsening of your general condition. Call your local emergency number without delay.
If you experience any side effect not listed here, or if any side effect becomes severe, contact your healthcare provider. Reporting side effects helps regulators monitor the safety of medicines. In the EU, side effects can be reported to the national pharmacovigilance system; in the US, via the FDA's MedWatch program; and in the UK, via the MHRA Yellow Card Scheme.
How Should You Store NovoRapid FlexTouch?
Proper storage is essential to maintain insulin potency and patient safety. Insulin that has been frozen, overheated or stored beyond its shelf life can lose effectiveness without any visible change in appearance, potentially leading to unexpected hyperglycemia.
Unopened pens (not yet in use): Store in the refrigerator at 2 °C to 8 °C. Keep away from the freezer compartment and cooling element. Never freeze insulin — frozen insulin must be discarded because the protein structure is destroyed. Unopened pens stored correctly can be used until the expiration date printed on the label and outer carton. Keep the carton closed to protect from light.
In-use pens (after first use): After the first use, the pen can be stored at room temperature below 30 °C for up to 28 days. Do not refrigerate a pen that is in use, because cold insulin is more painful to inject. After 28 days, discard the pen even if insulin remains. Writing the date of first use on the pen helps track the 28-day window.
General precautions: Protect the pen from direct sunlight and heat sources. Do not leave the pen in a hot car, near a window in direct sunlight, near a radiator or in checked airline luggage (where cargo-hold temperatures can drop below freezing). When travelling, carry insulin in hand luggage and use an insulated case — but avoid placing ice packs in direct contact with the pen. Before each injection, visually inspect the insulin: the solution should appear clear and colourless, like water. Do not use if it is cloudy, discoloured or contains visible particles or strings.
Disposal: Used pen needles and expired pens must be disposed of in an approved sharps container according to local regulations. Needles should never be placed in household waste because of the risk of needlestick injury. Many pharmacies and healthcare facilities offer sharps collection services. Keep all insulin and needles out of the reach and sight of children.
What Does NovoRapid FlexTouch Contain?
Knowing the full composition of NovoRapid FlexTouch helps patients and healthcare providers identify potential allergens and understand why each ingredient is included. Each component has a specific pharmaceutical purpose.
Active ingredient: Insulin aspart – 100 units per mL (equivalent to approximately 3.5 mg per mL). Insulin aspart is a modified human insulin analogue produced by recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast). The substitution of proline with aspartic acid at position B28 prevents the formation of stable hexamers, enabling rapid absorption.
Inactive ingredients (excipients):
- Glycerol (glycerin) – Isotonic agent that matches the formulation to body fluids, reducing discomfort on injection.
- Phenol – Antimicrobial preservative that maintains sterility once the pen is in use.
- Metacresol (m-cresol) – Antimicrobial preservative working alongside phenol; also helps stabilize the insulin hexamer and monomer equilibrium.
- Zinc chloride – Stabilizes the insulin molecule and prolongs shelf life.
- Disodium hydrogen phosphate dihydrate – pH buffer maintaining formulation stability.
- Sodium chloride – Adjusts tonicity.
- Sodium hydroxide / hydrochloric acid – Used to adjust pH to approximately 7.4, within physiological range.
- Water for injection – Pharmaceutical-grade water used as the solvent for the solution.
The solution is clear and colourless when properly stored. The FlexTouch pen itself is made from medical-grade plastic and contains a glass cartridge. Patients with known allergy to metacresol or phenol should inform their healthcare provider; although rare, these preservatives are a recognized cause of local allergic skin reactions. The pen does not contain latex and is considered suitable for people with latex allergy.
Frequently Asked Questions About NovoRapid FlexTouch
Medical References & Sources
All information in this article is based on peer-reviewed medical literature, international guidelines and regulatory agency product information. The following sources were used:
- European Medicines Agency (EMA). NovoRapid – Summary of Product Characteristics (SmPC). Committee for Medicinal Products for Human Use. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). NovoLog (insulin aspart) Prescribing Information. Novo Nordisk Inc. Last revised 2024. Available at: www.accessdata.fda.gov
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1). DOI: 10.2337/dc25-SINT
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. DOI: 10.2337/dci22-0034
- Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults: A Consensus Report by the ADA and EASD. Diabetes Care. 2021;44(11):2589-2625. DOI: 10.2337/dci21-0043
- ISPAD (International Society for Pediatric and Adolescent Diabetes). Clinical Practice Consensus Guidelines 2022. Pediatric Diabetes. 2022;23(8).
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management (NG17). Last updated 2022.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Last updated 2022.
- British National Formulary (BNF). Insulin aspart. National Institute for Health and Care Excellence. 2025.
- Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabetic Medicine. 1993;10(6):535-539.
- Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine. 2000;17(11):762-770.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition. Brussels: IDF; 2021.
About Our Medical Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed physicians and pharmacists specializing in endocrinology, diabetology and clinical pharmacology. All content follows our strict editorial standards based on the GRADE evidence framework.
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔍 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✏️ Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in endocrinology, diabetology, clinical pharmacology and internal medicine.